The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ivanov S.V.

State Research Institute for Complex Issues of Cardiovascular Diseases Municipal Budget Healthcare Institution, Kemerovo, Russia

Kharkova G.S.

Mental health research center, Ministry of Science and High Education of RF, Moscow, Russia

Smulevich A.B.

Sechenov First Moscow State Medical University of Ministry of health of the Russia, Moscow, Russia

Morozova Ya.V.

Russian Cardiology Research and Production Complex, Moscow, Russia;
Ltd 'CrioCenter', Moscow, Russia

The use of the concentrate of nucleus containing cells of umbilical cord blood for treatment of asthenic disorders (schizoasthenia) in patients with schizophrenia with negative symptoms

Authors:

Ivanov S.V., Kharkova G.S., Smulevich A.B., Morozova Ya.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9): 68‑73

DOI: 10.17116/jnevro201911909168

Read: 1907 times

Download PDF (RU)
Contact the author
Table of contents

THE USE OF THE CONCENTRATE OF NUCLEUS CONTAINING CELLS OF UMBILICAL CORD BLOOD FOR TREATMENT OF ASTHENIC DISORDERS (SCHIZOASTHENIA) IN PATIENTS WITH SCHIZOPHRENIA WITH NEGATIVE SYMPTOMS
THE USE OF THE CONCENTRATE OF NUCLEUS CONTAINING CELLS OF UMBILICAL CORD BLOOD FOR TREATMENT OF ASTHENIC DISORDERS (SCHIZOASTHENIA) IN PATIENTS WITH SCHIZOPHRENIA WITH NEGATIVE SYMPTOMS

To cite this article:

Ivanov SV, Kharkova GS, Smulevich AB, Morozova YaV. The use of the concentrate of nucleus containing cells of umbilical cord blood for treatment of asthenic disorders (schizoasthenia) in patients with schizophrenia with negative symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9):68‑73. (In Russ.)
https://doi.org/10.17116/jnevro201911909168

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
PANSS six-factor model. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):28-34
Clinical and immu­nological rela­tionships in patients with early schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):35-42
Clinical and psychopathological features of treatment-resistant schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50
Cognitive vascular diso­rders and morphometric para­meters of the prefrontal, dorsolateral cortex and thalamus in post-stroke patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):91-95
The effect of Mexi­dol on the level of neurogenesis markers in acute cere­brovascular acci­dent in the expe­riment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):107-112
The study of the beha­vioral reactions and dura­tion of ultrasonic voca­lization in rats from fema­les stre­ssed during pregnancy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):117-123
Analysis of cognitive status in patients with different noso­logies and clinical variants of very late mani­festing schi­zophreniform psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):88-93
Modern concepts of sleep disturbances asso­ciated with mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):7-12
Asso­ciation of cortisol levels with psychopathological features of depression and therapeutic response in female patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):45-54
Factors supporting chro­nic inflammation in mental illness. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):7-15
Abstract:

Objective. To assess the safety and efficacy of umbilical cord blood (UCB) cells in the treatment of schizoasthenia and comorbid negative disorders. Material and methods. The study was conducted in men (n=15) with remission of schizophrenia with a predominance of asthenic disorders (ICD-10 items F20.6 and F21.5). Patients received intravenous infusions of UCB cells at the average dose of 250 mln viable cells per infusion (4 injections at 2 week intervals). The efficacy and safety were assessed using the Positive and Negative Symptoms of Schizophrenia (PANSS), the General Clinical Impression Scale (CGI), Asthenia Scale MFI-20 3, the MATRIX Consensus Cognitive Battery (MCCB), the Clinical evaluation of adverse events (side effects). Results and conclusion. The infusions of UCB cells have a positive effect on asthenic disorders, increase the level of general activity and minimize cognitive impairments. The authors assume that UCB cells potentiate the activity of typical and atypical antipsychotics.

Keywords:

cord blood cells
schizophrenia
schizoasthenia
cognitive functions
neurogenesis

Authors:

Ivanov S.V.

State Research Institute for Complex Issues of Cardiovascular Diseases Municipal Budget Healthcare Institution, Kemerovo, Russia

Kharkova G.S.

Mental health research center, Ministry of Science and High Education of RF, Moscow, Russia

Smulevich A.B.

Sechenov First Moscow State Medical University of Ministry of health of the Russia, Moscow, Russia

Morozova Ya.V.

Russian Cardiology Research and Production Complex, Moscow, Russia;
Ltd 'CrioCenter', Moscow, Russia

Close metadata

References:

  1. Mayer-Gross W. Die Klinik. Handbuck der Geistes Krankheiten (Herausgegeben Von Bumke). 1932.
  2. Ey H. Etudes psychiatriques I. Paris. 1955.
  3. Glatzel J. Periodische versagenzustande im vorfeld schizophrener psychosen. Forschr Neurol und Psychiat. 1968;36:509-526.
  4. Kaplinskij MZ. Postanovka voprosa o roli astenii v techenii shizophrenicheskogo processa. Tr. Institute im. Gannushkina. M. 1936;1:229-236. (In Russ.)
  5. Smulevich AB, Vorob’ev VYu. Psikhopatologiya shizofrenicheskogo defekta. Zhurnal Nevropatologii i Psikhiatrii im. S.S. Korsakova. 1988;88:100-105. (In Russ.)
  6. Vnukov VA. O defekte pri shizofrenicheskom protsesse. Tr. 2-go Vsesoyuznogo s’ezda psikhiatrov i nevropatologov. M. 1937;466-470. (In Russ.)
  7. Janzarik W. Dynamische grundkonstellationen in endogenen psychosen. Berlin. 1969.
  8. Smulevich AB, Dubnitskaya EB. Asteniya I komorbidnye psihicheskie rasstroistva. Zhurnal Psihiatriya i Psihopharmakoterapiya im. P.B. Gannushkina. 2009;04:4-7. (In Russ.)
  9. Huber G. Reine Defektsyndrome und Basisstadien endogener Psychosen. Fortschr Neurol Psychiatr. 1966;34:409-426.
  10. Huber G. Das Konzept substratnaher Basissymptome und seine Bedeutung fur Theorie und Therapie schizophrener Erkrankungen. Nervenarzt. 1983;54:23-32.
  11. Smulevich AB, Dubnitskaya EB, Pavlova LK, Morozova YaV. Primenenie koncentrata kletok pupovinoi krovi v terapii ipihondricheskih remissii pri shizophrenii. M. 2011;134-147.
  12. Terapevticheskii potencial kletok pupovinnoi krovi pri negematologicheskih zabolevaniyah. Pod red. Palceva M.A., Smirnova V.N. M. 2011. (In Russ.)
  13. Smulevich AB, Dubnitskaya EB, Voronova EI, Morozova YaV, Radaev SM. Effektivnost kletok pupovinoi krovi u pacientov s terapevticheski rezistentnymi depressiyami. Zhurnal Kletochnye Tehnologii v Biologii i Medicine. 2015;4:279-285. (In Russ.)
  14. Sugaya K. Stem cell strategies, future and beyond. Seishin Shinkeigaku Zasshi. 2003;105(1):68-80.
  15. Saito T. Study on mental diseases: neual stem cells. Seishin Shinkeigaku Zasshi. 2005;107(6):612-618.
  16. Kay SR, Fiszbein A, Lindenmayer JP, Opler LA. Positive and negative syndromes in schizophrenia as a function of chronicity. Acta Psychiatr Scand. 1986;74:507-518.
  17. Guy W. ECDEU Assessment Manual for Psycho-pharmacology. Rockville, Md: U.S. National Institute of Health; 1976.
  18. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39(3):315-325.
  19. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR. The MATRICS Consensus Cognitive Battery, Part 1, Test Selection, Releability, and Validity. Am J Psychiatry. 2008;165:203-213.
  20. Dollfus S, Lyne J. Negative symptoms: history of the concept and their position in diagnosis of schizophrenia. Schizophr Res. 2016;8.
  21. Mucci A. The evolution of negative symptom constructs. Paper presented at: Congress of the European Psychiatric Association. (Florence, Italy). 2017;1-4.
  22. Polishuk IA. Znachenie osobennostei organizma i sledovyh faktorov v patogeneze shizophrenii i maniakalno-depressivnogo psihoza. Kiev. 1956. (In Russ.)
  23. Rukovodstvo po psikhiatrii. Pod red. Snezhnevskogo A.V. M.: Meditsina; 1983. (In Russ.)
  24. Joseph J, Kremen WS, Franz CE, Glatt SJ, van de Leemput J, Chandler SD, Tsuang MT, Twamley EW. Predictors of current functioning and functional decline in schizophrenia. Schizophr Res. 2017.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.